Geert Wanten

Dr. Geert Wanten

Department of Gastroenterology and Hepatology, Radboud University Medical Centre, 6525 GA Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EOEvelyn D. Olthof
Evelyn D. Olthof
MVMichelle W. Versleijen
Michelle W. Versleijen
GWGetty Huisman–De Waal
Getty Huisman–De Waal
TFTon Feuth
Ton Feuth
WKWietske Kievit
Wietske Kievit
GWGeert Wanten
Geert Wanten
Patients on home parenteral nutrition (HPN) are at risk for catheter-related complications; mainly infections and occlusions. We have previously shown in HPN patients presenting with catheter sepsis that catheter locking with taurolidine dramatically reduced re-infections when compared with heparin. Our HPN population therefore switched from heparin to taurolidine in 2008. The aim of the present study was to compare long-term effects of this catheter lock strategy on the occurrence of catheter-related bloodstream infections and occlusions in HPN patients. Data of catheter-related complications were retrospectively collected from 212 patients who received HPN between January 2000 and November 2011, comprising 545 and 200 catheters during catheter lock therapy with heparin and taurolidine, respectively. We evaluated catheter-related bloodstream infection and occlusion incidence rates using Poisson-normal regression analysis. Incidence rate ratios were calculated by dividing incidence rates of heparin by those of taurolidine, adjusting for underlying disease, use of anticoagulants or immune suppressives, frequency of HPN/fluid administration, composition of infusion fluids, and duration of HPN/fluid use before catheter creation. Bloodstream infection incidence rates were 1.1/year for heparin and 0.2/year for taurolidine locked catheters. Occlusion incidence rates were 0.2/year for heparin and 0.1/year for taurolidine locked catheters. Adjusted incidence ratios of heparin compared to taurolidine were 5.9 (95% confidence interval, 3.9–8.7) for bloodstream infections and 1.9 (95% confidence interval, 1.1–3.1) for occlusions. Given that no other procedural changes than the catheter lock strategy were implemented during the observation period, these data strongly suggest that taurolidine decreases catheter-related bloodstream infections and occlusions in HPN patients compared with heparin.

1 April 2015 in Clinical Nutrition
Verified
Journal Article
Closed access
EOE.D. Olthof
E.D. Olthof
RNReindert Nijland
Reindert Nijland
AGA.F. Gülich
A.F. Gülich
GWGeert Wanten
Geert Wanten

1 December 2018 in Clinical Nutrition
Verified
Journal Article
Closed access
DDDorian N. Dijxhoorn
Dorian N. Dijxhoorn
MBManon G.A. van Den Berg
Manon G.A. van Den Berg
WKWietske Kievit
Wietske Kievit
JKJulia W. Korzilius
Julia W. Korzilius
JDJoost Drenth
Joost Drenth
GWGeert Wanten
Geert Wanten

1 February 2016 in Clinical Nutrition
Verified
Journal Article
Closed access
ENE.G. Neelis
E.G. Neelis
ARA.M. Roskott
A.M. Roskott
GDGerard Dijkstra
Gerard Dijkstra
GWGeert Wanten
Geert Wanten
MSM.J. Serlie
M.J. Serlie
EREdmond Rings
Edmond Rings

15 July 2015 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
GWGeert Wanten
Geert Wanten

10 February 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
DDDane Christina Daoud
Dane Christina Daoud
GWGeert Wanten
Geert Wanten
FJFrancisca Joly
Francisca Joly
Catheter-related bloodstream infection (CRBSI) is one of the most common and potentially fatal complications in patients receiving home parenteral nutrition (HPN). In order to prevent permanent venous access loss, catheter locking with an antimicrobial solution has received significant interest and is often a favored approach as part of the treatment of CRBSI, but mainly for its prevention. Several agents have been used for treating and preventing CRBSI, for instance antibiotics, antiseptics (ethanol, taurolidine) and, historically, anticoagulants such as heparin. Nonetheless, current guidelines do not provide clear guidance on the use of catheter locks. Therefore, this review aims to provide a better understanding of the current use of antimicrobial locking in patients on HPN as well as reviewing the available data on novel compounds. Despite the fact that our current knowledge on catheter locking is still hampered by several gaps, taurolidine and ethanol solutions seem promising for prevention and potentially, but not proven, treatment of CRBSI. Additional studies are warranted to further characterize the efficacy and safety of these agents.